文献速递乳房整形与再造

疾病修饰抗风湿药对自身免疫性结缔组织病患者植入物乳房重建结局的影响

Do disease-modifying anti-rheumatic drugs affect implant-based breast reconstruction outcomes in patients with autoimmune connective tissue disease?
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2025-08-12

基于TrinetX数据库的倾向性评分匹配研究纳入两组各1262例自身免疫性结缔组织病患者,比较使用与未使用疾病修饰抗风湿药(DMARDs)者接受植入物乳房重建的结局。结果显示DMARD组在90天内坏死和手术部位疼痛风险更高,2年内感染、深静脉血栓、肺栓塞、急诊就诊、手术部位疼痛和包膜切除术风险更高;传统DMARDs组2年内包膜挛缩风险高于生物制剂DMARDs组。

要点

  • DMARDs组90天内坏死(OR 1.86)和手术部位疼痛(OR 1.43)风险更高。
  • DMARDs组2年内感染、DVT、PE、急诊就诊、疼痛和包膜切除术风险更高。
  • 传统DMARDs较生物制剂DMARDs的2年包膜挛缩风险更高(OR 3.29)。

核心结论

  • 使用DMARDs的自身免疫性结缔组织病患者在植入物乳房重建后90天和2年内更易出现不良结局。
  • 传统DMARDs患者2年内包膜挛缩风险高于生物制剂DMARDs患者。

研究设计与样本

  • 基于TrinetX数据库的回顾性队列研究,经1:1倾向性评分匹配两组各1262例。

主要发现

  • 90天内DMARD组坏死OR 1.86(P=0.03),手术部位疼痛OR 1.43(P=0.01)。
  • 2年内DMARD组感染OR 1.35(P=0.04),DVT OR 1.76(P=0.01),PE OR 2.52(P=0.001)。
  • 2年内DMARD组急诊就诊OR 1.21(P=0.03),手术部位疼痛OR 1.46(P=0.001),包膜切除术OR 1.30(P=0.04)。
  • 传统DMARDs较生物制剂DMARDs的2年包膜挛缩OR 3.29(P=0.001)。

临床怎么用

  • 整形外科医生应认识DMARDs相关术后并发症风险以改善患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As breast implants gain popularity, there remains concern over implant safety. Roughly 8% of the U.S population lives with an autoimmune disease, yet there is a paucity of literature comparing outcomes between patients taking disease-modifying anti-rheumatic drugs (DMARDs) and those not taking DMARDs undergoing implant-based breast reconstruction. METHODS: The TrinetX database identified 2 cohorts of 1262 patients each: those with an autoimmune connective tissue disease on a DMARD, and subsequently underwent implant-based breast reconstruction, and those with similar diagnoses undergoing the same procedure, without prior exposure to DMARDs. Demographics and comorbidities were matched via a 1:1 propensity-score analysis to identify predictors of postoperative outcomes within 90-days and 2-years. RESULTS: Within 90 days, DMARD patients had higher odds of necrosis (OR 1.86, P = 0.03) and surgical site pain (OR 1.43, P = 0.01). Within 2 years, DMARD patients had higher odds of postoperative infection (OR 1.35, P = 0.04), DVT (OR 1.76, P = 0.01), PE (OR 2.52, P = 0.001), emergency room (ER) visit (OR 1.21, P = 0.03), surgical site pain (OR 1.46, P = 0.001), and capsulectomy (OR 1.30, P = 0.04). Patients on conventional DMARDs were found to have increased odds of capsular contracture within 2 years compared to patients on biologic DMARDs (OR 3.29, P = 0.001). CONCLUSION: Patients on DMARDs were more likely to experience negative postoperative outcomes within 90 days and 2 years, with increased capsular contracture risk in those taking conventional DMARDs. Plastic surgeons should be cognizant of these postoperative complications to improve patient outcomes.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Fung E, Roth JM, Shaari DS, et al. Do disease-modifying anti-rheumatic drugs affect implant-based breast reconstruction outcomes in patients with autoimmune connective tissue disease? J Plast Reconstr Aesthet Surg. 2025. PMID: 40816167. doi:10.1016/j.bjps.2025.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。